

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Genscript Biotech Corporation**

**金斯瑞生物科技股份有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1548)**

## **CHANGE OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG**

The board of directors (the “**Board**”) of Genscript Biotech Corporation (the “**Company**”) hereby announces that the Company’s principal place of business in Hong Kong has been changed to 40th Floor, Dah Sing Financial Centre, No. 248 Queen’s Road East, Wanchai, Hong Kong with effect from 26 March 2021.

Saved for the change of building name, the physical location of the Company’s principal place of business in Hong Kong remains unchanged.

By order of the Board  
**Genscript Biotech Corporation**  
**Mr. Meng Jiange**  
*Chairman and Executive Director*

Hong Kong, 26 March 2021

*As at the date of this announcement, the executive Directors are Mr. Meng Jiange, Ms. Wang Ye and Dr. Zhu Li; the non-executive Directors are Dr. Wang Luquan, Mr. Pan Yuexin and Ms. Wang Jiafen; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian, Mr. Pan Jiuan and Dr. Wang Xuehai.*

\* For identification purposes only